Fibrosis: A key feature of Fabry disease with potential therapeutic implications

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Weidemann, Frank ^a   Sanchez Niño, Maria D ^b   Politei, Juan ^c   Oliveira, João Paulo ^d   Wanner, Christoph ^a   Warnock, David G ^e   Ortiz, Alberto ^f  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c Neurology Department   (Argentina)

^d Centro Hospitalar Universitário de São João   (Portugal)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f 28400 Madrid   (Spain)

Author keywords

Enzyme replacement therapy; Fabry; Fibrosis; Heart; Kidney; Lyso Gb3; Podocyte

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA GALACTOSIDASE; COLLAGEN TYPE 4; CREATINE PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; GLYCOSPHINGOLIPID; N ACETYLASPARTIC ACID;

ALBUMINURIA; APOPTOSIS; ASTROCYTOSIS; BRAIN ISCHEMIA; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL OBSERVATION; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FIBROSING ALVEOLITIS; FIBROSIS; GLOMERULOSCLEROSIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HETEROZYGOTE; HIGH ENERGY PHOSPHATE; HUMAN; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE BASEMENT MEMBRANE; MICROGLIA; MICROVASCULATURE; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TRANSPLANTATION; PATHOGENESIS; PODOCYTE; REVIEW; TISSUE INJURY; TREATMENT RESPONSE; WHITE MATTER LESION;

ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FIBROSIS; HUMANS; KIDNEY;

EID: 84881046462     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-116     Document Type: Review

References (108)

1. Fabry disease. Germain DP, Orphanet J Rare Dis 2010 5 30 10.1186/1750-1172-5-30 21092187
2. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP, Mol Genet Metab 2008 93 112 128 10.1016/j.ymgme.2007.09.013 18037317
3. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, Schiffmann R, Virchows Arch 2007 451 823 834 10.1007/s00428-007-0468-6 17674039 (Pubitemid 47497940)
4. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG, Nat Clin Pract Nephrol 2008 4 327 336 10.1038/ncpneph0806 18431378 (Pubitemid 351769331)
5. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van BW, Vanholder R, Wanner C, Nephrol Dial Transplant 2013 28 505 517 10.1093/ndt/gfs526 23234755
6. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N, J Am Soc Nephrol 2007 18 1547 1557 10.1681/ASN.2006080816 17409312 (Pubitemid 46717522)
7. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. Tahir H, Jackson LL, Warnock DG, J Am Soc Nephrol 2007 18 2609 2617 10.1681/ASN.2006121400 17656478 (Pubitemid 47378878)
8. ECM remodeling in hypertensive heart disease. Berk BC, Fujiwara K, Lehoux S, J Clin Invest 2007 117 568 575 10.1172/JCI31044 17332884 (Pubitemid 46348511)
9. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Campanholle G, Ligresti G, Gharib SA, Duffield JS, Am J Physiol Cell Physiol 2013 304 591 C603 10.1152/ajpcell.00414.2012 23325411
10. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. Iredale JP, J Clin Invest 2007 117 539 548 10.1172/JCI30542 17332881 (Pubitemid 46348508)
11. Mechanisms of tubulointerstitial fibrosis. Zeisberg M, Neilson EG, J Am Soc Nephrol 2010 21 1819 1834 10.1681/ASN.2010080793 20864689
12. Focal segmental glomerulosclerosis. D'Agati VD, Kaskel FJ, Falk RJ, N Engl J Med 2011 365 2398 2411 10.1056/NEJMra1106556 22187987
13. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S, Kidney Int 2002 62 901 913 10.1046/j.1523-1755.2002.00528.x 12164872 (Pubitemid 35316719)
14. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC III, Diabetes 2008 57 1439 1445 10.2337/db08-0061 18511444
15. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Ziyadeh FN, Kidney Int 1993 43 114 120 10.1038/ki.1993.19 8433550 (Pubitemid 23167454)
16. Reversal of lesions of diabetic nephropathy after pancreas transplantation. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M, N Engl J Med 1998 339 69 75 10.1056/NEJM199807093390202 9654536 (Pubitemid 28304880)
17. Agalsidase benefits renal histology in young patients with Fabry disease. Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E, J Am Soc Nephrol 2013 24 137 148 10.1681/ASN.2012030316 23274955
18. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ, Proc Natl Acad Sci U S A 2008 105 2812 2817 10.1073/pnas.0712309105 18287059 (Pubitemid 351723626)
19. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Boutin M, Gagnon R, Lavoie P, Auray-Blais C, Clin Chim Acta 2012 414 273 280 23041216
20. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE, Biochim Biophys Acta 1812 2011 70 76
21. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Tondel C, Bostad L, Hirth A, Svarstad E, Am J Kidney Dis 2008 51 767 776 10.1053/j.ajkd.2007.12.032 18436087 (Pubitemid 351626251)
22. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, Noel LH, Grunfeld JP, Valbuena C, Oliveira JP, Muller J, Breunig F, Zhang X, Warnock DG, Nephrol Dial Transplant 2010 25 2168 2177 10.1093/ndt/gfp528 19833663
23. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Valbuena C, Carvalho E, Bustorff M, Ganhao M, Relvas S, Nogueira R, Carneiro F, Oliveira JP, Virchows Arch 2008 453 329 338 10.1007/s00428-008- 0653-2 18769939
24. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R, Kidney Int 1978 13 223 235 10.1038/ki.1978.32 418264 (Pubitemid 8304328)
25. Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. Kahn P, J Neurol Neurosurg Psychiatry 1973 36 1053 1062 10.1136/jnnp.36.6.1053 4204059
26. Renal pathology in Fabry disease. Alroy J, Sabnis S, Kopp JB, J Am Soc Nephrol 2002 13 Suppl 2 134 S138 12068025
27. Fabry disease: a morphologic study of 11 cases. Fischer EG, Moore MJ, Lager DJ, Mod Pathol 2006 19 1295 1301 10.1038/modpathol.3800634 16799480 (Pubitemid 44423075)
28. The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology. Weidemann F, Niemann M, Ertl G, Stork S, J Am Soc Echocardiogr 2010 23 793 801 10.1016/j.echo.2010.05.020 20591620
29. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM, Eur Heart J 2007 28 1228 1235 10.1093/eurheartj/ehm153 17483538 (Pubitemid 47343855)
30. Cardiac challenges in patients with Fabry disease. Weidemann F, Linhart A, Monserrat L, Strotmann J, Int J Cardiol 2010 141 3 10 10.1016/j.ijcard.2009. 08.002 19720409
31. Prominent papillary muscles in Fabry disease: a diagnostic marker? Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J, Stork S, Voelker W, Ertl G, Wanner C, Weidemann F, Ultrasound Med Biol 2011 37 37 43 10.1016/j.ultrasmedbio.2010.10.017 21084151
32. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM, Eur Heart J 2003 24 2151 2155 10.1016/j.ehj.2003.09.017 14643276 (Pubitemid 37486535)
33. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM, Eur Heart J 2005 26 1221 1227 10.1093/eurheartj/ ehi143 15728649 (Pubitemid 40863129)
34. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J, Circulation 2009 119 524 529 10.1161/CIRCULATIONAHA.108.794529 19153271
35. Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Hasegawa H, Takano H, Shindo S, Takeda S, Funabashi N, Nakagawa K, Toyozaki T, Kuwabara Y, Komuro I, Circulation 2006 113 720 e721 10.1161/CIRCULATIONAHA.105. 584292 16636179
36. The Fabry cardiomyopathy: models for the cardiologist. Weidemann F, Niemann M, Warnock DG, Ertl G, Wanner C, Annu Rev Med 2011 62 59 67 10.1146/annurev-med-090910-085119 21090963
37. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F, JACC Cardiovasc Imaging 2011 4 592 601 10.1016/j.jcmg.2011.01.020 21679893
38. Astroglia in CNS injury. Hatten ME, Liem RK, Shelanski ML, Mason CA, Glia 1991 4 233 243 10.1002/glia.440040215 1827781
39. Delayed and remote effects of focal cortical infarctions: secondary damage and reactive plasticity. Witte OW, Stoll G, Adv Neurol 1997 73 207 227 8959216
40. Fabry disease: immunocytochemical characterization of neuronal involvement. DeVeber GA, Schwarting GA, Kolodny EH, Kowall NW, Ann Neurol 1992 31 409 415 10.1002/ana.410310410 1375013
41. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Okeda R, Nisihara M, Neuropathology 2008 28 532 540 10.1111/j.1440-1789.2008.00883.x 18410273
42. Kidney histologic alterations in alpha-Galactosidase-deficient mice. Valbuena C, Oliveira JP, Carneiro F, Relvas S, Ganhao M, Sa-Miranda MC, Rodrigues LG, Virchows Arch 2011 458 477 486 10.1007/s00428-011-1051-8 21328014
43. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Najafian B, Svarstad E, Bostad L, Gubler MC, Tondel C, Whitley C, Mauer M, Kidney Int 2011 79 663 670 10.1038/ki.2010.484 21160462
44. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW, Circulation 2009 119 2561 2567 10.1161/CIRCULATIONAHA.108.841494 19414635
45. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, Tome MT, McKenna WJ, Lee P, Camici PG, Heart 2006 92 357 360 16085718
46. Fabry disease model: a rational approach to the management of Fabry disease. Wanner C, Clin Ther 2007 29 Suppl A 2 S5
47. Images in cardiovascular medicine. Myocardial fibrosis in fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings. Funabashi N, Toyozaki T, Matsumoto Y, Yonezawa M, Yanagawa N, Yoshida K, Komuro I, Circulation 2003 107 2519 2520 10.1161/01.CIR.0000062036.35852.01 12756193 (Pubitemid 36605238)
48. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P, Cardiovasc Pathol 2010 19 293 301 10.1016/j.carpath.2009.05.003 19631563
49. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D, Arterioscler Thromb Vasc Biol 2006 26 839 844 10.1161/01.ATV.0000209649.60409.38 16469946 (Pubitemid 43732160)
50. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 479 482 10.1080/10976640600605002 16755835
51. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Park JL, Shu L, Shayman JA, Am J Physiol Heart Circ Physiol 2009 296 1133 H1140 10.1152/ajpheart.00929.2008 19202000
52. The cerebral vasculopathy of Fabry disease. Moore DF, Kaneski CR, Askari H, Schiffmann R, J Neurol Sci 2007 257 258 263 10.1016/j.jns.2007.01.053 17362993 (Pubitemid 46856501)
53. Pathogenesis of leukoaraiosis: a review. Pantoni L, Garcia JH, Stroke 1997 28 652 659 10.1161/01.STR.28.3.652 9056627 (Pubitemid 27118393)
54. Central nervous system fibrosis is associated with fibrocyte-like infiltrates. Aldrich A, Kielian T, Am J Pathol 2011 179 2952 2962 10.1016/j.ajpath.2011.08.036 22015460
55. Astrocytes express type VIII collagen during the repair process of brain cold injury. Hirano S, Yonezawa T, Hasegawa H, Hattori S, Greenhill NS, Davis PF, Sage EH, Ninomiya Y, Biochem Biophys Res Commun 2004 317 437 443 10.1016/j.bbrc.2004.03.049 15063777 (Pubitemid 38452502)
56. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Das AM, Naim HY, Adv Clin Chem 2009 49 57 71 19947355
57. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Machann W, Breunig F, Weidemann F, Sandstede J, Hahn D, Kostler H, Neubauer S, Wanner C, Beer M, Eur J Heart Fail 2011 13 278 283 10.1093/eurjhf/hfq211 21149315
58. Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease. Palecek T, Bultas J, Hajek M, Karetova D, Kuchynka P, Kautzner J, Elleder M, Linhart A, Int J Cardiol 2010 144 337 339 10.1016/j.ijcard.2009.03.045 19344961
59. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, Brady RO, Sokoloff L, Moore DF, J Neurochem 2001 79 1217 1224 11752062 (Pubitemid 34019799)
60. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM, Mol Genet Metab 2004 82 93 97 10.1016/j.ymgme.2004.01.011 15110329 (Pubitemid 38523330)
61. A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV. Maalouf K, Jia J, Rizk S, Brogden G, Keiser M, Das A, Naim HY, J Inherit Metab Dis 2010 33 445 449 10.1007/s10545-010-9114-6 20495958
62. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A, Nephrol Dial Transplant 2011 26 1797 1802 10.1093/ndt/gfq306 20504837
63. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG, Nephrol Dial Transplant 2009 24 1736 1743 10.1093/ndt/gfp105 19293136
64. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG, Nephrol Dial Transplant 2010 25 769 775 10.1093/ndt/gfp554 19846394
65. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. Sanchez-Nino MD, Sanz AB, Ruiz-Andres O, Poveda J, Izquierdo MC, Selgas R, Egido J, Ortiz A, Cytokine Growth Factor Rev 2013 24 23 40 10.1016/j.cytogfr.2012.08.001 22959722
66. The MIF receptor CD74 in diabetic podocyte injury. Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A, J Am Soc Nephrol 2009 20 353 362 10.1681/ASN.2008020194 18842989
67. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM, Biochim Biophys Acta 2010 1802 741 748 10.1016/j.bbadis.2010.05.003 20471476
68. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE, PLoS One 2012 7 47805 10.1371/journal.pone.0047805 23094092
69. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, Desnick RJ, J Comput Assist Tomogr 2004 28 158 168 10.1097/00004728-200403000- 00002 15091117 (Pubitemid 38364978)
70. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Marodi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG, Clin J Am Soc Nephrol 2010 5 2220 2228 10.2215/CJN.04340510 20813854
71. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Marodi L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C, Nephrol Dial Transplant 2012 27 1042 1049 10.1093/ndt/gfr420 21804088
72. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Kramer J, Niemann M, Liu D, Hu K, Machann W, Beer M, Wanner C, Ertl G, Weidemann F, Eur Heart J 2013 34 1587 1596 10.1093/eurheartj/eht098 23520186
73. Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge. Weidemann F, Sommer C, Duning T, Lanzl I, Mohrenschlager M, Naleschinski D, Arning K, Baron R, Niemann M, Breunig F, Schaefer R, Strotmann J, Wanner C, Am J Med 2010 123 658 20609689
74. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Weidemann F, Niemann M, Herrmann S, Kung M, Stork S, Waller C, Beer M, Breunig F, Wanner C, Voelker W, Ertl G, Bijnens B, Strotmann JM, Eur Heart J 2007 28 3020 3026 10.1093/eurheartj/ehm454 17981828 (Pubitemid 350262257)
75. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM, Am J Cardiol 2005 96 842 846 10.1016/j.amjcard.2005.05.033 16169374 (Pubitemid 41319722)
76. Diffuse structural and metabolic brain changes in Fabry disease. Marino S, Borsini W, Buchner S, Mortilla M, Stromillo ML, Battaglini M, Giorgio A, Bramanti P, Federico A, De SN, J Neurol 2006 253 434 440 10.1007/s00415-005- 0020-z 16541218 (Pubitemid 43965607)
77. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. O'Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS, J Neurol Neurosurg Psychiatry 2004 75 441 447 10.1136/jnnp.2003.014910 14966162 (Pubitemid 38338776)
78. Magnetic resonance image findings in 5 young patients with Fabry disease. Politei JM, Capizzano AA, Neurologist 2006 12 103 105 10.1097/01.nrl. 0000187495.16824.a6 16534447
79. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Simmons ML, Frondoza CG, Coyle JT, Neuroscience 1991 45 37 45 10.1016/0306-4522(91)90101-S 1754068
80. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. Fellgiebel A, Mazanek M, Whybra C, Beck M, Hartung R, Muller KM, Scheurich A, Dellani PR, Stoeter P, Muller MJ, J Neurol 2006 253 780 787 10.1007/s00415-006-0118-y 16511647 (Pubitemid 43980150)
81. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R, Brain Res Bull 2003 62 231 240 10.1016/j.brainresbull.2003.09.021 14698356 (Pubitemid 38091711)
82. FLAIR and diffusion MRI signals are independent predictors of white matter hyperintensities. Maillard P, Carmichael O, Harvey D, Fletcher E, Reed B, Mungas D, DeCarli C, AJNR Am J Neuroradiol 2013 34 54 61 10.3174/ajnr.A3146 22700749
83. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Schermuly I, Muller MJ, Muller KM, Albrecht J, Keller I, Yakushev I, Beck M, Fellgiebel A, Eur J Neurol 2011 18 347 353 10.1111/j.1468-1331.2010. 03155.x 20636371
84. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, N Engl J Med 2001 345 9 16 10.1056/NEJM200107053450102 11439963 (Pubitemid 32634266)
85. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Schaefer RM, Tylki-Szymanska A, Hilz MJ, Drugs 2009 69 2179 2205 10.2165/11318300-000000000-00000 19852524
86. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO, JAMA 2001 285 2743 2749 10.1001/jama.285.21.2743 11386930 (Pubitemid 32525371)
87. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB, Heart 2008 94 153 158 10.1136/hrt.2006.104026 17483124 (Pubitemid 351211719)
88. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM, Circulation 2003 108 1299 1301 10.1161/01.CIR. 0000091253.71282.04 12952834 (Pubitemid 37174405)
89. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C, J Intern Med 2013 http://onlinelibrary.wiley.com/doi/10.1111/joim. 12077/abstract [Epub ahead of print]
90. Standards of medical care in diabetes - 2012. American Diabetes Association, Diabetes Care 2012 35 Suppl 1 11 S63 22187469
91. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. KDIGO, Kidney Int Supplements 2012 2013 3 1 150
92. Liver fibrosis. Bataller R, Brenner DA, J Clin Invest 2005 115 209 218 15690074 (Pubitemid 40385459)
93. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. Burstein B, Nattel S, J Am Coll Cardiol 2008 51 802 809 10.1016/j.jacc.2007.09.064 18294563 (Pubitemid 351260071)
94. The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study http://www.clinicaltrials.gov/ct2/show/NCT00446862, accessed on March 11, 2013 23864212
95. Optimization of concomitant medication in Fabry cardiomyopathy. Close L, Elliott P, Acta Paediatr Suppl 2007 96 81 83 17391449 (Pubitemid 46481124)
96. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. De ZD, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D, Lancet 2010 376 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
97. The expanding spectrum of biological actions of vitamin D. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J, Nephrol Dial Transplant 2010 25 2850 2865 10.1093/ndt/gfq313 20525641
98. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD, JAMA 2012 307 674 684 10.1001/jama.2012.120 22337679
99. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F, Kidney Int 2011 79 1236 1243 10.1038/ki.2011.33 21368745
100. The transforming growth factor-Beta signaling pathway involvement in cardiovascular lesions in mucopolysaccharidosis-I. Yano S, Li C, Pavlova Z, JIMD Rep 2013 7 55 58 23430495
101. Notch3 and kidney injury: never two without three. Sanchez-Nino MD, Ortiz A, J Pathol 2012 228 266 273 10.1002/path.4101 22952000
102. Aldosterone antagonists-last man standing? Armstrong PW, N Engl J Med 2011 364 79 80 10.1056/NEJMe1012547 21073364
103. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Young MJ, Rickard AJ, Mol Cell Endocrinol 2012 350 248 255 10.1016/j.mce.2011.09.008 21930186
104. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. Alvarez-Prats A, Hernandez-Perera O, Diaz-Herrera P, Ucero AC, Anabitarte-Prieto A, Losada-Cabrera A, Ortiz A, Rodriguez-Perez JC, Nephrol Dial Transplant 2012 27 2720 2733 10.1093/ndt/gfr671 22302208
105. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ, Circulation 2001 104 317 324 10.1161/hc2801.094031 11457751 (Pubitemid 32666954)
106. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process. Rodrigues DR, Rodrigues-Diez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodriguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M, PLoS One 2010 5 14145 10.1371/journal.pone.0014145 21152444
107. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, Tseng CD, Tseng YZ, Chiang FT, Lin JL, Circulation 2008 117 344 355 10.1161/CIRCULATIONAHA.107.695346 18172037
108. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Savelieva I, Kakouros N, Kourliouros A, Camm AJ, Europace 2011 13 308 328 10.1093/europace/eur002 21345926